Pharmaceutical Technology
DECEMBER 16, 2022
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% GnRH antagonists have an improved safety and efficacy profile compared to the marketed GnRH agonists, which have significant side effects that are unappealing to patients. of 7MM sales.
Pharmaceutical Technology
DECEMBER 7, 2022
On 29 November, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) warned of some new and potentially serious eye-related side effects associated with Dupixent, an interleukin (IL)-4/13 inhibitor drug used in the treatment of numerous allergic indications such as atopic dermatitis, asthma and nasal polyps.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MAY 25, 2023
The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. There was no significant difference in side effect profiles of the two vaccines, based on the data. percentage points (96% CI, −0.3 for serogroup W to 20.5
European Pharmaceutical Review
OCTOBER 12, 2022
The safety data from the trial was consistent with earlier trial data. This is promising when side effects such as ARIAs are often detected in magnetic resonance imaging brain scans of patients who are given the antibodies. If the drug is approved, GlobalData estimates that global sales for HMTM will reach $127 million by 2030.
Medico Reach
FEBRUARY 8, 2023
from 2022 to 2030, the pharma industry will reach USD 9,241.34 million by 2030. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. from 2023 to 2030. Poised to grow at a CAGR of 29.4% The global pharmacovigilance (PV) market stood at USD 7.80
European Pharmaceutical Review
MARCH 24, 2023
Pegozafermin also has a favourable safety and tolerability profile, with few gastrointestinal (GI) side effects. In the European Union, NASH affects nearly 10 million people and is expected to increase by more than 40 percent by 2030. It is becoming the leading cause for liver transplants.
pharmaphorum
SEPTEMBER 30, 2022
. “What we cannot know yet is whether that effect increases over time in an individual. Another key factor to consider is the safety profile of the drug, particularly with regard to amyloid-related imaging abnormalities (ARIA) that are always a risk with amyloid-targeting drugs, causing oedema (ARIA-E) and haemorrhages (ARIA-H).
Expert insights. Personalized for you.
59 
Let's personalize your content